The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
Clinical trial NCT05092802 · UNKNOWN
Trial details
- NCT number
- NCT05092802
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-23
- Primary completion
- 2023-05-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.